Related Experiment Videos
Imatinib mesylate
1College of Pharmacy, Washington State University, Spokane, WA, USA.
Abstract:
Imatinib is an example of a new group of drugs being developed using the principle of molecular targeting. Imatinib is able to kill the cancer cells and not the body's healthy cells. Imatinib mesylate is indicated for the treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors and patients with Philadelphia chromosome-positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alfa.
Insights
Imatinib is a molecularly targeted drug that selectively eliminates cancer cells. It is approved for treating specific gastrointestinal stromal tumors and Philadelphia chromosome-positive chronic myeloid leukemia.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Imatinib represents a novel class of molecularly targeted cancer therapies.
- This drug demonstrates selective cytotoxicity towards cancer cells, sparing healthy tissues.
- Its development is based on the principle of targeting specific molecular pathways driving cancer growth.
Purpose of the Study:
- To outline the therapeutic indications for imatinib mesylate.
- To highlight its mechanism of action in targeting cancer cells.
Main Methods:
- Review of clinical data and drug development principles.
- Identification of specific patient populations and cancer types responsive to imatinib.
Main Results:
- Imatinib mesylate is indicated for Kit (CD117)-positive unresectable or metastatic gastrointestinal stromal tumors.
- It is also indicated for Philadelphia chromosome-positive chronic myeloid leukemia in various phases, including post-interferon-alfa failure.
Conclusions:
- Imatinib mesylate is a key therapeutic agent in molecularly targeted cancer treatment.
- Its efficacy is demonstrated in specific hematologic and solid tumors characterized by distinct molecular markers.